Johnson & Johnson (J&J) has announced plans to acquire V-Wave, a company specializing in heart failure implants, in a deal that could total $1.7 billion. The acquisition includes an upfront payment of $600 million, with the potential for an additional $1.1 billion in milestone payments. V-Wave, which will join J&J’s medtech division, develops innovative cardiovascular implants targeting heart failure with reduced ejection fraction (HFrEF), a condition where the heart struggles to pump sufficient blood. The deal is expected to close by the end of 2024.
This acquisition marks J&J's continued focus on expanding its presence in the heart disease device market. Earlier in 2024, J&J acquired Shockwave Medical for $13.1 billion, bringing pioneering intravascular lithotripsy catheters into its portfolio. This followed a $16.6 billion purchase of Abiomed, known for its miniature heart pumps, and a $400 million acquisition of cardiac implant developer Laminar. V-Wave’s Ventura Interatrial Shunt, designed to manage heart failure by reducing left atrial pressure, complements J&J's strategy to address critical gaps in cardiovascular care.
J&J's acquisition of V-Wave aligns with its broader strategy to enhance its cardiovascular offerings and meet unmet medical needs. The Ventura Interatrial Shunt, which received FDA breakthrough device designation in 2019, offers a minimally invasive solution for heart failure patients. J&J executives emphasized the company's commitment to innovative heart failure treatments, noting their long-standing relationship with V-Wave since their initial investment in 2016. Despite the anticipated short-term financial impact, J&J believes this acquisition will ultimately strengthen its leadership in cardiovascular care.
Click here to read the original news story.